Estudio de utilización tipo consumo de los medicamentos Lopinavir-ritonavir en el tratamiento de la primera línea en VIH-1 en Colombia para los años 2011 y 2013

The human immunodeficiency virus type I (HIV-1) is known worldwide for the damage that can cause in the immune system to people who are infected, affecting CD4 T lymphocytes, either for unprotected sexual activity, Drug addiction, among others. This disease can have different characteristics, depending on the age, sex, race and / or geographic location of the patient. In Colombia this disease is characterized by being ruinous and catastrophic of high cost as defined by decree 2699 of 2007 in Article 1. The prevalence of HIV-1 in Colombia as dictated by the bulletin of the year2015 Current situation the adjusted prevalence was 0.13 %. The incidence that was presented and reported in the bulletin of the year 2015 is 15.4 per 100,000 inhabitants. There are antiretroviral drug groups, one of which is protease inhibitors (PIs), blocking an HIV enzyme called protease. When the protease is blocked, the two drugs in combination Lopinavir-Ritonavir And can reduce the concentration of HIV in the body. Lopinavir is an HIV-1 protease inhibitor, Ritonavir inhibits the cytochrome P450-mediated metabolism of Lopinavir, thus providing increased plasma levels of Lopinavir. The protease enzyme functions as a chemical scissors cutting the raw material Of HIV, ie large viral proteins in small pieces or new particles of HIV that are necessary to build a new virus, protease inhibitors interfere with such scissors, preventing virus replication, creating non-infectious virions. When the study of the use of Lopinavir-Ritonavir drugs was carried out, it was possible to conclude that the highest rate of DDD use occurs in the age group of 35 to 54 years, evidencing a relevance in pharmacotherapy for the treatment of HIV-1 From the point of view of dosage ranges and treatment regimens, observing the complete and correct use of the management guides for patients and is being correctly prescribed, thus achieving a rational use of these drugs. Since this age has a better progression of the treatment, the costs of the therapy are assumed, since also in that age range patients have a better adherence to the treatment with a greater attendance of patients in the department of Bogotá for the year 2013

• Autores: Forero Galindo, Francy Milena; Garay González, Laura Viviana
• Tipo de recurso: Trabajo de grado de pregrado
• Fecha de publicación: 2017
• Institución: Universidad de Ciencias Aplicadas y Ambientales U.D.C.A
• Repositorio: Repositorio Institucional UDCA
• Idioma: spa
• OAI Identifier: oai:repository.udca.edu.co:11158/708
• Acceso en línea: https://repository.udca.edu.co/handle/11158/708
• Palabra clave: Lopinavir; Ritonavir; VIH; VIH - Tratamiento con drogas; Lopinavir; Ritonavir
• Rights: closedAccess
• License: Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales